Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and DDI Study of Fenebrutinib (GDC-0853)
NCT02699710Phase 1Completed
- Sponsor
- Genentech
- Start
- Sep 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fenebrutinib in rheumatoid arthritis (RA) (3 arms), sponsored by Genentech. Primary endpoints: Relative Bioavailability of GDC-0853 tablet Compared to GDC-0853 Capsule, Area Under the Concentration Time-Curve From Time 0 to Infinity and 14 more. Started Sep 2015; status: completed.
02
Drugs
fenebrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02699710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02699710.